Amneal Set To Debut US Byetta Competition – Two Decades After Market Entry
One Of First GLP-1 Generics To Receive US FDA Approval; Follows Recent Liraglutide AG
The first GLP-1 agonist to receive US Food and Drug Administration approval, Byetta (exenatide), has generic competition at last, with Amneal bagging the first rival after Teva seemingly abandoned its proposed generic version.
